-
A hundred flowers bloom!
Time of Update: 2021-06-22
*Only for medical professionals to read for reference, Fudan Cancer Masters Interpretation of 2021 ASCO Urinary Tumor Diagnosis and Treatment New Progress! The 2021 American Society of Clinical Oncol
-
The three pillars of hematological tumors｜ASCO 2021
Time of Update: 2021-06-22
The long-term follow-up data of GC012F in the treatment of relapsed and refractory MM multi-center clinical GC012F, developed by Genxi Biotechnology, is a BCMA/CD19 dual-targeting autologous CAR-T cell therapy .
The announcement this time is a phase Ib clinical study of the product for peripheral T-cell lymphoma .
-
FDA guidelines for patient reporting outcomes in cancer trials measure five core concepts
Time of Update: 2021-06-22
In 2016, Paul Kluetz, the current deputy director of OCE, and FDA colleagues published an article encouraging separate PRO evaluations of the three core concepts in cancer clinical research (symptomatic adverse events, physical function, and disease-related symptoms) instead of Use static health-related quality of life tools .
-
Express GRAIL launches early screening blood test for multiple cancers, more than 50 types of cancer can be found in one routine blood draw
Time of Update: 2021-06-22
"Reference: [1] GRAIL Presents Interventional PATHFINDER Study Data at 2021 ASCO Annual Meeting and Introduces Galleri, a Groundbreaking Multi-Cancer Early Detection Blood Test.
com/press-releases /grail-presents-interventional-pathfinder-study-data-at-2021-asco-annual-meeting-and-introduces-galleri-a-groundbreaking-multi-cancer-early-detection-blood-test/[2] Interim Results of PATHFINDER, a Clinical Use Study Using a Methylation-Based Multi‑Cancer Early Detection Test.
-
2021 ICML Chinese Expert Oral Report & Poster Presentation The Most Complete Summary
Time of Update: 2021-06-22
Zhang Unit: Peking Union Medical College Hospital 03 Abstract Number: 163 Title: Lenalidomide and rituximab regimen combined with intravitreal methotrexate followed by lenalidomide maintenance for primary vitreoretinal lymphoma: a prospective phase II study.
-
Chinese strong voice!
Time of Update: 2021-06-22
0001, compared with placebo combined with GP, carrelizumab combined with GP increased PFS, It reduces the risk of disease progression or death by 50%; there is no statistical difference in ORR and disease control rate (DCR); in terms of DoR, the two groups are 9.
-
Nat Commun: Genomic research may reveal potential combination therapy or effective treatment of triple-negative breast cancer
Time of Update: 2021-06-22
Recently, a research report entitled "In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy" was published in the international journal Nature Communications .
-
Multiple studies by the team of Professor Chunhong Hu and Associate Professor Wu Fang were selected for the 2021 ASCO Annual Meeting
Time of Update: 2021-06-22
2021 American Society of Clinical Oncology (ASCO) Annual Meeting will be held online from June 4th to June 8th .
A postoperative recurrence of non-small cell lung cancer related genes and tumor immune microenvironment characteristics.
Subgroup-level network meta-analysis for efficacy of first-line immunotherapy-based treatments in advanced non-small cell lung cancer.
-
[One picture, one drug] Sotorasib, a NSCLC drug targeted for the treatment of KRAS G12C mutations, was launched
Time of Update: 2021-06-22
Sotorasib is currently the only targeted drug approved to market for the treatment of locally advanced or metastatic NSCLC patients with KRASG12C mutations.
-
Jalova China is approved, opening a new chapter in the first-line treatment of follicular lymphoma
Time of Update: 2021-06-22
A few days ago, another blockbuster innovative drug has been added to the field of lymphoma treatment, the new generation of anti-CD20 monoclonal antibody Jialuohua® (English name: Gazyva®, generic name: otuzumab) has officially been approved by the National Medical Products Administration (NMPA) of China Approved, combined with chemotherapy, for initial treatment of stage II adult patients with large masses, stage III or IV follicular lymphoma, and patients who have achieved at least partial remission and subsequent single-agent maintenance therapy .
-
Sansheng Guojian HER2/PD-1 bispecific antibody was approved by the U.S. FDA...
Time of Update: 2021-06-22
On June 14th, Sansheng Guojian announced that a clinical trial evaluating the bispecific antibody SSGJ-705 has recently been approved by the U.
SSGJ-705 is a recombinant anti-HER2 x anti-PD-1 bispecific antibody injection (abbreviated as "BsAb") .
-
Another milestone in the treatment of gastrointestinal tumors!
Time of Update: 2021-06-22
Thierry Andre, First-line therapy of pembrolizumab versus standard of care (SOC) in microsatelliteinstability-high/mismatch repair deficient metastatic colorectal cancer: The phase III, KEYNOTE-177 study.
, Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).
-
King of the world, Abexili combined with endocrine therapy for Chinese patients with early breast cancer, the risk of postoperative recurrence is greatly reduced by 34.3%
Time of Update: 2021-06-22
Based on this, monarchE research came into being as needed, through the combined use of CDK4/6 inhibitors and endocrine therapy drugs for the adjuvant treatment of hormone receptor-positive but HER2-negative breast cancer with a high risk of recurrence .
-
Advanced Materials breakthrough!
Time of Update: 2021-06-22
The paper, the study describes a liposomal drug delivery system (S1P/JS-K/Lipo) that delivers nitric oxide (NO) prodrug JS-K, using sphingosine 1-phosphate (S1P) signaling The molecule acts as an active targeting lipid ligand and acts on GBM tumors .
-
Tumor vaccine has been designated by the FDA for fast-track entry for the treatment of recurrent gliomas, Dr. Mai Meng broke the news
Time of Update: 2021-06-22
Recent popular reports from Yimaike ★ Invitation to the event 2021 Oncolytic Virus Drug Development Forum will open in Shanghai /MedClub News/--Recently, VBI VACCINES announced that VBI-1901, which uses granulocyte macrophage colony stimulating factor (GM-CSF) as an adjuvant, has been granted Fast Track designation by the FDA for the treatment of first relapse Patients with glioblastoma (GBM) .
-
EHA2021 Huaxia Yingtai CD19/CD20 Dual STAR-T treatment of R/R B-ALL releases the latest data and new observations
Time of Update: 2021-06-22
The “Innovative CD 19/CD 20 Dual STAR-T Cells for Treatment of Refractory/Relapsed (R/R) Acute B Lymphocytic Leukemia (R/R B-ALL)” jointly launched by Huaxia Yingtai and Lu Daopei Hospital is honored to be one of the few Many were selected as one of the researches of the EHA conference special report .
-
Fosun Kate FKC876 New Indication Approved for Clinical Clinic
Time of Update: 2021-06-22
About FKC876 FKC876 is a CAR-T cell therapy product that Fosun Kite introduced Yescarta (axicabtagene ciloleucel) technology from Kite (a subsidiary of Gilead) in the United States in early 2017 for industrialization in China .
-
Significant progress in Molecular Cancer!
Time of Update: 2021-06-22
On June 11, 2021, the Chen Junxia team of Chongqing Medical University published an online study titled "The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC" in Molecular Cancer (IF=15.
-
To see the future, gynecological tumor treatment ushered in a "window of opportunity" 2021 ASCO gynecological tumor special
Time of Update: 2021-06-22
The NeoPembrOv study (NCT03275506) is a multicenter, open-label, non-controlled, randomized phase II clinical trial, which aims to explore the initial unresectable FIGO stage IIIC/IV ovarian, fallopian tube or peritoneal advanced high-grade serous carcinoma (HGSC ) In patients, whether the addition of pembrolizumab (P) during neoadjuvant carboplatin-paclitaxel chemotherapy (CP) can increase the maximum tumor reduction rate [by the complete resection rate (CRR) after intermediate cytoreduction (IDS) Evaluation] .
-
Professor Zhang Li: J-ALEX is researching and reforming the idea of ALK inhibitors "arranging troops", "drugs" can achieve the greatest benefit by making the best use of them. 2021 ASCO
Time of Update: 2021-06-22
Professor Zhang Li said: "The five-year follow-up data of the J-ALEX study announced at this ASCO conference shows that the five-year survival rate of the crizotinib group and the aletinib group is extremely equal.
